相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
Michael Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from the Phase 1/2 BRUIN Study
Michael Wang et al.
BLOOD (2020)
VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma
Michael Wang et al.
BLOOD (2020)
Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001
Maria Lia Palomba et al.
BLOOD (2020)
One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Michael Wang et al.
BLOOD (2020)
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
David J. Andorsky et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma
Peter Martin et al.
BLOOD (2019)
Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma
Anita Kumar et al.
HAEMATOLOGICA (2019)
Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies
Kerry A. Rogers et al.
LEUKEMIA (2019)
IBRUTINIB WITH RITUXIMAB (IR) AND SHORT COURSE R-HYPERCVAD/MTX IS VERY EFFICACIOUS IN PREVIOUSLY UNTREATED YOUNG PTS WITH MANTLE CELL LYMPHOMA (MCL)
M. Wang et al.
HEMATOLOGICAL ONCOLOGY (2019)
Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
Craig H. Moskowitz et al.
BLOOD (2019)
Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma
Changying Jiang et al.
BLOOD (2019)
Safety and Anti-Tumor Activity Study of Loncastuximab Tesirine and Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
Julien Depaus et al.
BLOOD (2019)
Triangle: Autologous Transplantation after a Rituximab/Ibrutinib/ara-c Containing Induction in Generalized Mantle Cell Lymphoma - a Randomized European MCL Network Trial
Martin Dreyling et al.
BLOOD (2019)
Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton's Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies
Chan Y. Cheah et al.
BLOOD (2019)
Frontline Treatment with Ibrutinib with Rituximab (IR) Combination Is Highly Effective in Elderly (≥65 years) Patients with Mantle Cell Lymphoma (MCL) - Results from a Phase II Trial
Preetesh Jain et al.
BLOOD (2019)
Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell Lymphoma
Jonathon B. Cohen et al.
BLOOD (2019)
Maintenance Rituximab Improves Outcomes in Mantle Cell Lymphoma Patients Who Respond to Induction Therapy with Bendamustine plus Rituximab without Autologous Transplant
Brian T. Hill et al.
BLOOD (2019)
Long-Term Outcomes with Ibrutinib Versus the Prior Regimen: A Pooled Analysis in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL) with up to 7.5 Years of Extended Follow-up
Simon Rule et al.
BLOOD (2019)
Leukemic Non-nodal Mantle Cell Lymphoma: Diagnosis and Treatment
Akriti Gupta Jain et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Paul M. Barr et al.
BLOOD (2019)
Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines
Stephen J. Schuster et al.
BLOOD (2019)
Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Yuqin Song et al.
BLOOD (2019)
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era
James N. Gerson et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab
Vera Dufner et al.
BLOOD ADVANCES (2019)
Ibrutinib resistance in mantle cell lymphoma: clinical, molecular and treatment aspects
Oshrat Hershkovitz-Rokah et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)
Preetesh Jain et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
Constantine S. Tam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The B cell receptor signaling pathway in mantle cell lymphoma
Maria I. Merolle et al.
Oncotarget (2018)
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma
Jia Ruan et al.
BLOOD (2018)
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Marco Ruella et al.
NATURE MEDICINE (2018)
Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!
Martin Dreyling et al.
BLOOD (2018)
Long-Term Follow-up of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma
Michael Wang et al.
BLOOD (2018)
Safety and Efficacy of Acalabrutinib Plus Bendamustine and Rituximab (BR) in Patients With Treatement-Naive (TN) or Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
Tycel J. Phillips et al.
BLOOD (2018)
Syk inhibitors in clinical development for hematological malignancies
Delong Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
Georg Hess et al.
LEUKEMIA & LYMPHOMA (2017)
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
S. Le Gouill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy
Christian W. Eskelund et al.
BLOOD (2017)
Observation as the initial management strategy in patients with mantle cell lymphoma
P. Abrisqueta et al.
ANNALS OF ONCOLOGY (2017)
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib
Tracy E. Wiczer et al.
BLOOD ADVANCES (2017)
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling et al.
ANNALS OF ONCOLOGY (2017)
Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis
Francois Caron et al.
BLOOD ADVANCES (2017)
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
Paul M. Barr et al.
BLOOD (2016)
Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma
Jonathon B. Cohen et al.
CANCER (2016)
Antibody Drug Conjugates (ADCs): Changing the Treatment Landscape of Lymphoma
Deepa Jagadeesh et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase study
Martin Dreyling et al.
LANCET (2016)
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine et al.
LANCET (2016)
Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial
Michael L. Wang et al.
LANCET ONCOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial).
Mathias J. Rummel et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Production of Anti-CD19 CAR T Cells for ZUMA-3 and-4: Phase 1/2 Multicenter Studies Evaluating KTE-C19 in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (R/R ALL)
Marianna Sabatino et al.
BLOOD (2016)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Tadeusz Robak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma
Jia Ruan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma
Kami Maddocks et al.
BLOOD (2015)
Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
Xiaoxian Zhao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
Brad S. Kahl et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Design and development of therapies using chimeric antigen receptor-expressing T cells
Gianpietro Dotti et al.
IMMUNOLOGICAL REVIEWS (2014)
Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase
Kevin S. Currie et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213
S. H. Bernstein et al.
ANNALS OF ONCOLOGY (2013)
SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma
Maria Carmela Vegliante et al.
BLOOD (2013)
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
Francesco Merli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC plus autologous stem-cell support: still very long survival but late relapses do occur
Christian H. Geisler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang et al.
LANCET ONCOLOGY (2012)
Treatment of Older Patients with Mantle-Cell Lymphoma
H. C. Kluin-Nelemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
Jonathan W. Friedberg et al.
BLOOD (2011)
Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes
Karin E. Smedby et al.
SEMINARS IN CANCER BIOLOGY (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
Jorge E. Romaguera et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
A. Goy et al.
ANNALS OF ONCOLOGY (2009)
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre phase 2 clinical trial
Owen A. O'Connor et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
Thomas M. Habermann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype
Ana Mozos et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
Eva Hoster et al.
BLOOD (2008)
The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma
T Katzenberger et al.
BLOOD (2006)
Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network
M Dreyling et al.
BLOOD (2005)
Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma
JE Romaguera et al.
CANCER (2003)
Blastic variant of mantle cell lymphoma:: a rare but highly aggressive subtype
M Bernard et al.
LEUKEMIA (2001)
分享论文
